Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Diane M. Da Silva(University of Southern California), W. Martin Kast(University of Southern California), Joseph G. Skeate(University of Southern California), Heather A. Lankes(Nationwide Children's Hospital), Sharad Ghamande(Augusta University Health), Jyoti Mayadev(University of California San Diego Medical Center), Danielle Enserro(NRG Oncology), Yvonne G. Lin(Florida State University), Michael J. Birrer(University of Arkansas Medical Center), Russell J. Schilder(Yamagata University), Koji Matsuo(University of Southern California), Huyen Q. Pham(University of Southern California), Katherine Moxley(Oklahoma Cancer Specialists and Research Institute)
Cited by 71
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851